Skip to content

Barbara O Rothbaum

16 papers in the library · 229 citations · publishing 2017-2026

Papers

Sort Most recent Most cited

Post-psychedelic and meditation-related challenges: a protocol for a mixed-methods longitudinal-observational study

medRxiv October 29, 2026 J. Lipson, Nicholas K. Canby, Z. Salako et al. preprint

Introduction: Psychedelics and meditation are increasingly used for therapeutic and wellness purposes. However, research into adverse effects (AEs) has been limited, without adequate investigation of the nature, clinical characteristics, and diversity of persisting challenges following psychedelic use and meditation practice. This study aims to better characterize the clinical and contextual...

Psilocybin-Assisted Early Palliative Care for Demoralization and Chronic Pain: An Open-Label Pilot Study.

medRxiv July 14, 2026 Ali J Zarrabi, Tanja Mletzko, George H. Grant et al. preprint

Demoralization, a syndrome of helplessness, hopelessness, and loss of meaning and chronic pain are common sources of distress in early palliative care. Psilocybin-assisted therapy (PAT) is an emerging intervention with preliminary data suggesting improvements in pain and demoralization. To date, PAT has not been studied among people living with both demoralization and chronic pain nor has it...

State of the Science: MDMA‐assisted psychotherapy for the treatment of posttraumatic stress disorder

Journal of Traumatic Stress March 12, 2026 Leslie A. Morland, Barbara O Rothbaum, Lauren M. Sippel et al. 2 citations

There is growing interest in novel approaches to treating posttraumatic stress disorder (PTSD), including the use of psychedelic substances combined with psychotherapy, often referred to as psychedelic-assisted therapy, to better meet the needs of patients who do not prefer or respond to traditional evidence-based treatments. Among these treatments, 3,4-methylenedioxymethamphetamine...

DOI: 10.1002/jts.70060 (opens in new tab) Posttraumatic stress Cognition Cognitive behavioral therapy Leverage statistics +9

Harnessing psychedelics for treating posttraumatic stress disorder: Does the science support all the hype?

Journal of Traumatic Stress May 7, 2025 Mark Creamer, Richard Bryant, Amy Lehrner et al. 1 citation

This paper is an edited transcript of a plenary panel held at the 2024 Annual Meeting of the International Society for Traumatic Stress Studies (ISTSS) in Boston, Massachusetts, United States. The panel comprised Drs. Mark Creamer (moderator), Richard Bryant (convenor), Amy Lehrner, Barbara O. Rothbaum, Joseph I. Ruzek, and Paula P. Schnurr. Bringing together clinicians and researchers with a...

DOI: 10.1002/jts.23163 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Mental health treatment PTSD Research Clinical trials +1

Treatment Approaches for Posttraumatic Stress Disorder Derived From Basic Research on Fear Extinction.

Biological Psychiatry February 15, 2025 Jessica L Maples-Keller, Laura E Watkins, Natalie Hellman et al. 12 citations

This brief review article will describe treatment approaches for posttraumatic stress disorder (PTSD) based on findings from basic research. The focus of this review will be fear conditioning and extinction models, which provide a translational model of PTSD that can help translate basic research in nonhuman animals through well-controlled trials confirming the efficacy of treatment approaches...

DOI: 10.1016/j.biopsych.2024.07.010 (opens in new tab) Full text (opens in new tab) Combination treatment Exposure therapy Fear extinction Translational +5

The METEMP protocol: Massed exposure therapy enhanced with MDMA for PTSD.

Contemporary Clinical Trials Communications February 1, 2025 Jessica L Maples-Keller, Boadie W Dunlop, Barbara O Rothbaum 5 citations

This article describes the rationale and the specific methods for an open label pilot trial of 100 mg MDMA in combination with massed exposure therapy for PTSD, a treatment which involves daily exposure therapy sessions for two weeks which has found to be effective. We review the need for novel PTSD treatments and the existing research on MDMA-assisted therapy, and then describe the rationale...

A critical evaluation of psilocybin-assisted therapy protocol components from clinical trial patients, facilitators, and caregivers.

Psychotherapy January 13, 2025 Roman Palitsky, Jessica L Maples-Keller, Caroline Peacock et al. 13 citations

Psilocybin-assisted therapy (PAT) is an experimental treatment with transformative promise. Developing standards for PAT psychotherapy protocols is a priority, but psychotherapeutic protocol components of PAT have been subjected to little rigorous research. This study was designed to assess protocol components in a trial of PAT. The Enhanced Critical Incident Technique (E-CIT) was used to...

DOI: 10.1037/pst0000551 (opens in new tab) Psychedelic therapy Psilocybin treatment Mental health care Therapeutic protocols +1

Reading the crowd: attitudes toward psychedelics and psychedelic therapies among attendees at a conference

Psychedelics December 17, 2024 Zachary Bosshardt, Jessica L Maples-Keller, Deanna M Kaplan et al.

Social attitudes, policy, and perceptions of psychedelics are currently undergoing considerable change. Growing public salience of psychedelics has been accompanied by the emergence of conferences focused on psychedelic education and dialogue. Attendees at such events compose an important group of stakeholders in psychedelic science and practice; their views of psychedelics can be valuable for...

DOI: 10.61373/pp024r.0040 (opens in new tab) Reading process Linguistics

Rapid Effects of MDMA Administration on Self-Reported Personality Traits and Affect State: A Randomized, Placebo-Controlled Trial in Healthy Adults.

Journal of Psychoactive Drugs October 23, 2024 Jessica L Maples-Keller, Courtland S Hyatt, Nathaniel L Phillips et al. 2 citations

3,4-methylenedioxymethamphetamine (MDMA) assisted therapy has been shown to be a safe and effective treatment for PTSD and emerging research suggests a change in personality traits may be a factor in treatment response. Most prior research on MDMA and personality has focused on cross-sectional comparisons of MDMA users and non-users; as such, well-controlled research assessing personality and...

DOI: 10.1080/02791072.2024.2420044 (opens in new tab) Full text (opens in new tab) Affect Clinical trial Psychedelic research Clinical psychology +3

A framework for assessment of adverse events occurring in psychedelic-assisted therapies

Journal of Psychopharmacology July 31, 2024 Roman Palitsky, Deanna M Kaplan, John Perna et al. 32 citations

Objective: Despite considerable research examining the efficacy of psychedelic-assisted therapies (PATs) for treating psychiatric disorders, assessment of adverse events (AEs) in PAT research has lagged. Current AE reporting standards in PAT trials are poorly calibrated to features of PAT that distinguish it from other treatments, leaving many potential AEs unassessed. Methods: A...

DOI: 10.1177/02698811241265756 (opens in new tab) Dosing Psychosocial Adverse effect Protocol science +6

A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults

Journal of Psychopharmacology February 15, 2022 Jessica L Maples-Keller, Seth D. Norrholm, Mark Burton et al. 53 citations

Background: Fear conditioning and extinction are well-characterized cross-species models of fear-related posttraumatic stress disorder (PTSD) symptoms, and recent animal data suggest that 3,4-methylenedioxymethamphetamine (MDMA) enhances fear extinction retention. Aims: This study investigated the effect of MDMA on fear learning, extinction training, and retention in healthy humans. Methods:...

A Mindfulness-Based Cognitive Therapy (MBCT) Intervention to Improve Resilience and Mitigate Symptoms of Burnout Syndrome in Critical Care Nurses: Results of a Randomized Trial

Open Journal of Nursing August 16, 2021 Meredith Mealer, Debra L Boeldt, Kathryn L Cochran et al.

Objective: Critical care nurses work in a challenging intensive care (ICU) environment that results in work-related psychological distress. Our objective was to pilot an in-person or virtual mindfulness-based cognitive therapy (MBCT) program enhanced resilience and a similarly designed attention control group. Methods: We randomized ICU nurses with symptoms of burnout syndrome and decreased...

A Multisite Randomized Controlled Trial of Mindfulness-Based Stress Reduction in the Treatment of Posttraumatic Stress Disorder.

Psychiatric Research and Clinical Practice October 1, 2019 Lori L. Davis, Charles Whetsell, Mark B Hamner et al.

Posttraumatic stress disorder (PTSD) is often difficult to treat, and many patients do not achieve full remission. Complementary and integrative health approaches, such as mindfulness meditation, are intended to be integrated with evidence-based treatment. This study examined the efficacy of mindfulness-based stress reduction (MBSR) in the treatment of PTSD in U.S. military veterans. Veterans...

Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) and R(-) MDMA on actigraphy-based daytime activity and sleep parameters in rhesus monkeys.

Experimental and Clinical Psychopharmacology June 25, 2018 Lais Fernanda Berro, Hannah Shields, Melis Odabas-Geldiay et al. 6 citations

(-) MDMA (0.3, 1.0, or 1.7 mg/kg) at 9 or 16 h (3 h before "lights off"). Morning treatments had no effects on sleep-like parameters. Racemic MDMA decreased general daytime activity during the first hour after injection and increased daytime activity at 3 hr posttreatment. Although afternoon administration of racemic MDMA increased sleep latency, it improved other sleep parameters, decreasing...

Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA)

Psychopharmacology July 24, 2017 Matthew B Young, Seth D. Norrholm, Lara M. Khoury et al. 103 citations

We validate enhancement of fear memory extinction by MDMA in a translational behavioral model, and reveal the importance of 5-HTT and 5-HT2A receptors to this effect. These observations support future clinical research of MDMA as an adjunct to exposure therapy, and provide important pharmacological considerations for clinical use in a population frequently treated with 5-HTT inhibitors.

DOI: 10.1007/s00213-017-4684-8 (opens in new tab) Full text (opens in new tab) MDMA Serotonin transporter Extinction optical mineralogy Pharmacology +2

Designing a Resilience Program for Critical Care Nurses.

AACN advanced critical care 2017 Meredith Mealer, Rachel M. Hodapp, David Conrad et al.

Workplace stress can affect job satisfaction, increase staff turnover and hospital costs, and reduce quality of patient care. Highly resilient nurses adapt to stress and use a variety of skills to cope effectively. To gain data on a mindfulness-based cognitive therapy resilience intervention for intensive care unit nurses to see if the intervention program would be feasible and acceptable....

DOI: 10.4037/aacnacc2017252 (opens in new tab) Full text (opens in new tab) Mindfulness Cognitive-behavioral therapy Focus groups Resilience